The drug discovery company last week announced a fund raising of 1.44m at 0.25p. This comes ahead of a pivotal period for the Cambridge based developer of therapies whose science is based on kinase inhibition, as it progresses its candidates towards the clinic. This comes just a few weeks after the early conclusion of Sareum’s Equity Swap Agreement with YA Global Master SPV (YAGM). The earlier facility agreed with YAGM in 2012 expires in September this year and we understand it is not m
